Bart Henderson

At Ironwood, we seek to transform knowledge into medicines that make a difference for patients. Patients shape our business. They influence our drugmaking process, helping us to understand and address their unmet medical needs, whether we’re creating a new medicine or tackling the equally challenging task of delivering that medicine to people around the world. Our employees shape our success. Since our founding in 1998, each of our employees has held shares in the company. Being owners of Ironwood means we are all careful stewards of our resources: we take a data-driven approach in which we celebrate definitive answers – whether those answers support holding steady or changing course – and we challenge every program to earn its way forward. Our discovery and development processes have generated a product that’s approved in the United States and in the European Union, as well as a robust pipeline. As we continue to do drugmaking well, we hope to inspire the support of our shareholders and earn the right to do it again – building an enduring pharmaceutical company that understands and addresses people’s needs.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Boston, MA.